Variant Gene Risk Allele Score vda Association Type Original DB Sentence supporting the association PMID PMID Year
dbSNP: rs113488022
rs113488022
0.800 GeneticVariation BEFREE In the real-life setting, activity and safety of BRAFi + MEKi in V600E BRAFm NSCLC are comparable to those observed in prospective clinical trials; the combination of BRAFi + MEKi is superior to monotherapy with a BRAFi. 31060855

2019

dbSNP: rs113488022
rs113488022
0.800 GeneticVariation BEFREE The US Food and Drug Administration approved a liquid biopsy test for EGFR-activating mutations in patients with non-small-cell lung cancer as a companion diagnostic for therapy selection. ctDNA also allows for the identification of mutations selected by treatment such as EGFR T790M in non-small-cell lung cancer. ctDNA can also detect mutations such as KRAS G12V in colorectal cancer and BRAF V600E/V600K in melanoma. 30883505

2019

dbSNP: rs113488022
rs113488022
0.800 GeneticVariation BEFREE Among the 53 NSCLC samples, only 5 (9.3%) cases harbored BRAF V600E mutation, 80% were of adenocarcinoma type, and the rest (20%) was of squamous cell carcinoma. 31781475

2019

dbSNP: rs113488022
rs113488022
0.800 GeneticVariation BEFREE Here, in this review, we outline the preclinical and clinical data for BRAF and MEK inhibitor combination treatment for NSCLC patients with BRAF V600E mutation. 29595366

2019

dbSNP: rs113488022
rs113488022
0.800 GeneticVariation BEFREE Dabrafenib Plus Trametinib for BRAF V600E-Mutant Non-small Cell Lung Cancer: A Patient Case Report. 31250402

2019

dbSNP: rs113488022
rs113488022
0.800 GeneticVariation BEFREE Molecular alterations that predict response to treatment (eg, EGFR mutations, ALK rearrangements, ROS1 rearrangements, and BRAF V600E mutations) are present in approximately 30% of patients with non-small cell lung cancer. 31454018

2019

dbSNP: rs113488022
rs113488022
0.800 GeneticVariation BEFREE The test was shown to accurately and reliably select patients with NSCLC with the <i>BRAF</i> V600E mutation for whom treatment with dabrafenib and trametinib is the optimal treatment. 29438093

2018

dbSNP: rs113488022
rs113488022
0.800 GeneticVariation BEFREE The US FDA approved a liquid biopsy test for EGFR activating mutations in patients with non-small cell lung cancer (NSCLC) as a companion diagnostic for therapy selection. ctDNA also allows for the identification of mutations selected by treatment such as EGFR T790M in NSCLC. ctDNA can also detect mutations such as KRAS G12V in colorectal cancer and BRAF V600E/V600K in melanoma. 30335711

2018

dbSNP: rs113488022
rs113488022
0.800 GeneticVariation BEFREE Due to the rarity of BRAF V600E mutation, no randomized study has compared the combination targeted therapy dabrafenib + trametinib with other second-line treatments for advanced or metastatic non-small-cell lung cancer (NSCLC). 29949047

2018

dbSNP: rs113488022
rs113488022
0.800 GeneticVariation BEFREE In the present review, we propose an overview of the available evidence about BRAF in NSCLC mutations (V600E and non-V600E), from biological significance to emerging clinical implications of BRAF mutations detection. 29729495

2018

dbSNP: rs113488022
rs113488022
0.800 GeneticVariation BEFREE BRAF inhibition has demonstrated anti-tumor activity in patients with BRAF V600E mutant NSCLC. 30019008

2018

dbSNP: rs113488022
rs113488022
0.800 GeneticVariation BEFREE This paper summarizes the clinical evidence that lead to the recent approval of the combination of dabrafenib and trametinib to treat patients with advanced NSCLC who harbor a BRAF V600E mutation. 29662327

2018

dbSNP: rs113488022
rs113488022
0.800 GeneticVariation BEFREE ICPi have favorable activity both in BRAF V600E and BRAF non-V600E mutant NSCLC. 29723688

2018

dbSNP: rs113488022
rs113488022
0.800 GeneticVariation BEFREE The vast majority of the BRAF V600E mutations were found in cerebral metastases of malignant melanomas and carcinomas (29/135, 22 %), with false-positive staining found in four breast cancer cases and two non-small-cell lung carcinoma (NSCLC) samples. 27350555

2016

dbSNP: rs113488022
rs113488022
0.800 GeneticVariation BEFREE Dabrafenib showed clinical activity in BRAF(V600E)-positive NSCLC. 27080216

2016

dbSNP: rs113488022
rs113488022
0.800 GeneticVariation BEFREE Dabrafenib plus trametinib could represent a new targeted therapy with robust antitumour activity and a manageable safety profile in patients with BRAF(V600E)-mutant NSCLC. 27283860

2016

dbSNP: rs113488022
rs113488022
0.800 GeneticVariation BEFREE Oncogenic BRAF V600E (BRAF(V600E)) substitutions are observed primarily in melanoma, colon cancer, and non-small cell lung cancer, but have been identified in multiple tumor types. 27048246

2016

dbSNP: rs113488022
rs113488022
0.800 GeneticVariation BEFREE Among 2690 patients with genotyped NSCLC during the study period, BRAF mutations were identified in 80 (3%) cases, consisting of V600E substitution in 42 (53%) cases; non-V600E mutation were observed in 38 (48%) cases. 26711930

2016

dbSNP: rs113488022
rs113488022
0.800 GeneticVariation BEFREE EGFR-Mediated Reactivation of MAPK Signaling Induces Acquired Resistance to GSK2118436 in BRAF V600E-Mutant NSCLC Cell Lines. 27196768

2016

dbSNP: rs113488022
rs113488022
0.800 GeneticVariation BEFREE Treatment of V600E BRAF-mutated NSCLC with BRAF inhibitor monotherapy demonstrated encouraging antitumor activity. 26301799

2015

dbSNP: rs113488022
rs113488022
0.800 GeneticVariation BEFREE In a recent phase II study for patients with BRAF-V600E non-small cell lung cancer</span> (NSCLC), BRAF V600E inhibitor demonstrated evidence of activity, but 30% of this selected group progressed while on treatment, suggesting a need for developing alternative strategies. 25706985

2015

dbSNP: rs113488022
rs113488022
0.800 GeneticVariation BEFREE Several retrospective studies on BRAF mutations in patients with NSCLC found that the majority of these mutations occur in adenocarcinomas and are V600E mutations. 26066373

2015

dbSNP: rs113488022
rs113488022
0.800 GeneticVariation BEFREE BRAF(V600E) cells with EGFR-driven resistance are characterized by hyperphosphorylated protein kinase AKT, a biomarker we validated in BRAF inhibitor-resistant NSCLC clinical specimens. 24550319

2014

dbSNP: rs113488022
rs113488022
0.800 GeneticVariation BEFREE Results of early-phase clinical trials and case reports demonstrate responses in V600E-mutant non-small-cell lung cancer, thyroid cancer, and hairy cell leukemia. 24955706

2014

dbSNP: rs113488022
rs113488022
0.800 GeneticVariation BEFREE NSCLC routinely tested for EGFR-mutations at Oslo University Hospital in the period February 2011-July 2013 were tested for V600E/K BRAF-mutations using a PCR-based method. 24552757

2014